AN2 Therapeutics | Investor Presentation Deck | 36 slides

AN2 Therapeutics · 2025-03
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

36
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide uses a three-column layout to summarize key strategic pillars.summarize
04
The slide uses a hub-and-spoke diagram to connect Boron to four therapeutic areas (Oncology, Inflammatory Response, Parasites, Bacterial Diseases).present_solution
Open slide detailBeat · Solution
05
The slide uses a Gantt-style chart to show the development stage of multiple drug candidates.plan_implementation
Open slide detailBeat · Solution
06
Uses a timeline-based framework to categorize clinical milestones and market opportunities.plan_implementation
Open slide detailLoop · Why Now
07
transition
Open slide detailLoop · Why Now
08
The slide combines a problem statement (clinical unmet need) with a market sizing chart.size_opportunity
Open slide detailBeat · Market Size
09
Includes clinical trial timeline diagram and outcome tables.show_traction
Open slide detailBeat · Market Size
10
The table uses blue highlighting to emphasize the higher severity metrics in the EBO Ph 2 group.compare_peers
Open slide detailBeat · Traction
11
LSM = Least squares mean. Data points include two LSM changes and two p-values.show_traction
Open slide detailBeat · Traction
12
The chart highlights a statistically significant improvement (p=0.036) at month 6.show_traction
Open slide detailBeat · Traction
13
The slide presents post-hoc analysis data for a clinical trial, highlighting a statistically significant improvement in the treatment group.show_traction
Open slide detailBeat · Traction
14
The slide presents TEAE (Treatment-emergent adverse events) and SAE (Serious adverse events) data.show_traction
Open slide detailBeat · Traction
15
Focuses on regulatory strategy and clinical trial progression for EBO-301.plan_implementation
16
The slide presents three line charts (A, B, C) comparing PBS, IMI (Imipenem), and two doses of EBO (EBO25, EBO50) over 4 weeks.show_traction
17
transition
18
Includes a map showing global distribution and a specific callout for US endemicity.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
19
The slide uses a central hub-and-spoke style diagram to connect funding sources with market potential.size_opportunity
Open slide detailBeat · ProblemLoop · Cost Of Inaction
20
The chart shows Log10 CFU counts in lungs for various treatment groups compared to untreated control.show_traction
Open slide detailLoop · Cost Of Inaction
21
The slide uses a dual-track timeline approach to show the progression from observational data collection to clinical trial phases.plan_implementation
Open slide detailLoop · Cost Of Inaction
22
transition
23
Includes a disease progression timeline diagram on the right.frame_problem
24
The slide uses a hub-and-spoke diagram to break down global prevalence numbers.size_opportunity
25
The slide uses a dot map to visualize geographic distribution of infections.size_opportunity
26
Includes chemical structure of the drug candidate.present_solution
27
The chart demonstrates superior efficacy of the lead compound over existing treatments (Benznidazole and E1224) in a model that mirrors human clinical outcomes.show_traction
28
compare_peers
29
plan_implementation
30
transition
31
The slide uses a hub-and-spoke diagram to connect Boron to various therapeutic areas, specifically focusing on oncology applications.present_solution
32
The slide uses a hub-and-spoke diagram to connect the central Boron element to four therapeutic areas, then maps those to two specific drug development programspresent_solution
33
transition
35
summarize
36
transition